Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

Itchy eczema in children finally gets relief

This is the first large-scale, randomized, placebo-controlled trial of a monoclonal antibody in any skin disease, including eczema, in children as young as six months. The study, which included 31 sites in Europe and North America, was published in The Lancet.

16 Sep 2022

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine, has received a four-year, $7.2 million grant from the NIH's National Institute of Child Health and Human Development renewing support for a Contraceptive Research Center at BUSM to further her research to develop innovative monoclonal antibody (mAb)-based contraceptive and multipurpose prevention technology (MPT) products.

15 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.

From AbbVie 8 Sep 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

In a recent study posted to the bioRxiv* preprint server, researchers at the U.S National Institutes of Health demonstrated the efficacy of molnupiravir and nirmatrelvir, two oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals in the rhesus macaque model, the closest proxy to humans.

7 Sep 2022

Novel P22-mAb based bELISA assay can help detect antibodies against African swine fever virus

African swine fever (ASF) is a highly infectious and fatal disease of pigs. Due to the complexity of the ASF virus (ASFV) and various clinical forms of the disease, a wide range of highly effective and robust sero-diagnostic assays are required.

2 Sep 2022

Research reveals administration of ineffective COVID-19 treatments after FDA deauthorization

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imdevimab) for the treatment of mild to moderate COVID-19 in high-risk, non-hospitalized patients.

30 Aug 2022

Survey reveals clear differences among the NYC boroughs in COVID behaviors and attitudes

As the nation follows new CDC recommendations to relax COVID-19 restrictions, a new survey of 2,500 New Yorkers conducted by the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) revealed clear differences among the boroughs in vaccine and booster uptake, childhood vaccination, treatment when sick and general trust in the safety and effectiveness of the vaccine.

24 Aug 2022

The safety, tolerability, and pharmacokinetics of a muco-trapping monoclonal antibody delivered by inhalation

Researchers conducted a phase I clinical trial of IN-006, an inhaled monoclonal antibody treatment for COVID-19.

24 Aug 2022

Study reveals safety and uptake of sotrovimab against severe SARS-CoV-2 infection in England

In a newly released study, researchers explored the sotrovimab uptake for severe COVID-19 prophylaxis and its safety across the community populations in England.

22 Aug 2022

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Researchers evaluated the neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 sub-variants by therapeutic monoclonal antibodies.

16 Aug 2022

Scientists explore nanomolar inhibition of SARS-CoV-2 infection via unmodified peptide targeting spike protein pre-hairpin intermediate

In a new study, scientists identified an unmodified peptide addressing pre-hairpin spike (S) protein intermediate inhibiting SARS-CoV-2 infection.

15 Aug 2022

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

A new study reviews recent advancements made in the development of RSV immunoprophylactic measures.

11 Aug 2022

Study identifies multiple pathways adopted by SARS-CoV-2 to develop resistance to nirmatrelvir

Researchers demonstrated multiple routes SARS-CoV-2 might take to develop high-level resistance to nirmatrelvir, an oral antiviral targeting the 3C-like protease (3CLpro) of SARS-CoV-2.

11 Aug 2022

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found.

10 Aug 2022

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Researchers assess the sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage to neutralization.

9 Aug 2022

Monoclonal Antibody News and Research

Further Reading

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

Study reveals increased immunity evasion by Omicron BA.2.75.2

Itchy eczema in children finally gets relief

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

All SARS-CoV-2 variants neutralized by a potent new antibody

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

Novel P22-mAb based bELISA assay can help detect antibodies against African swine fever virus

Research reveals administration of ineffective COVID-19 treatments after FDA deauthorization

Survey reveals clear differences among the NYC boroughs in COVID behaviors and attitudes

The safety, tolerability, and pharmacokinetics of a muco-trapping monoclonal antibody delivered by inhalation

Study reveals safety and uptake of sotrovimab against severe SARS-CoV-2 infection in England

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Scientists explore nanomolar inhibition of SARS-CoV-2 infection via unmodified peptide targeting spike protein pre-hairpin intermediate

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

Study identifies multiple pathways adopted by SARS-CoV-2 to develop resistance to nirmatrelvir

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®